Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23946005 | 0.98 | KDM4E (0.61) | KDM4EMAPK1HIF1APAOXEPHX1 | |
| SCHEMBL23560302 | 0.96 | KDM4E (0.59) | KDM4EMAPK1HIF1APAOXEPHX1 | |
| SCHEMBL22525950 | 0.96 | KDM4E (0.59) | KDM4EMAPK1HIF1APAOXEPHX1 | |
| SCHEMBL24508760 | 0.92 | CES2 (0.52) | KDM4EMAPK1HIF1APAOXCES2 | |
| SCHEMBL22802925 | 0.90 | CES2 (0.50) | KDM4EMAPK1HIF1APAOXCES2 | |
| SCHEMBL23945686 | 0.90 | CES2 (0.50) | KDM4EMAPK1HIF1APAOXCES2 | |
| SCHEMBL24891063 | 0.90 | CES2 (0.50) | KDM4EMAPK1HIF1APAOXCES2 | |
| SCHEMBL24508669 | 0.90 | KDM4E (0.61) | KDM4EMAPK1HIF1APAOXEPHX1 | |
| SCHEMBL19983194 | 0.90 | KDM4E (0.61) | KDM4EMAPK1HIF1APAOXEPHX1 | |
| SCHEMBL12566095 | 0.90 | SMN1; SMN2 (0.56) | KDM4EMAPK1HIF1APAOXACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | KDM4E 935/4885MAPK1 3746/4885HIF1A 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.